Latest Oncology News

EC-18 Reduces Duration and Incidence of Chemoradiation-Induced Oral Mucositis in Head and Neck Cancer

EC-18 Reduces Duration and Incidence of Chemoradiation-Induced Oral Mucositis in Head and Neck Cancer

October 21st 2021

Kristi Rosa

Treatment with the small molecule oral immunomodulator EC-18 resulted in a reduction in both the duration and incidence of severe oral mucositis in patients with head and neck cancer who are undergoing concurrent chemoradiation.

Abid on Optimizing COVID-19 Vaccines in CAR T-Cell Therapy Recipients

Abid on Optimizing COVID-19 Vaccines in CAR T-Cell Therapy Recipients

October 21st 2021

OncLive Staff

Dr. Abid discusses immune-compromising factors that are indigenous to CAR T-cell therapy recipients, the immunogenic potential of different COVID-19 vaccines, determinants of vaccine responses, and the potential need for booster vaccine dosing in this population.

TG-1701 Induces Strong Response Rates, Fewer AEs in Relapsed/Refractory CLL

TG-1701 Induces Strong Response Rates, Fewer AEs in Relapsed/Refractory CLL

October 21st 2021

Maggie Tibbitt

Chan Cheah, MBBS, discusses TG-1701 as a more target-specific BTK inhibitor, the outcomes in response rates in the cohorts of the trial, and where future research is headed with this agent.

Mutational Status Is Associated With Time to First Treatment in Newly Diagnosed CLL

Mutational Status Is Associated With Time to First Treatment in Newly Diagnosed CLL

October 21st 2021

Caroline Seymour

The presence of at least 1 mutation captured by next-generation sequencing was associated with a shorter time to first treatment among patients with newly diagnosed chronic lymphocytic leukemia, particularly those with mutations in POT1, ATM, FBXW7, and MYD88 genes.

Nivolumab/Chemo Approved in Europe for HER2– Advanced or Metastatic Gastric, GEJ, or Esophageal Adenocarcinoma

Nivolumab/Chemo Approved in Europe for HER2– Advanced or Metastatic Gastric, GEJ, or Esophageal Adenocarcinoma

October 21st 2021

Kristi Rosa

The European Commission has approved nivolumab plus fluoropyrimidine- and platinum-based chemotherapy for the frontline treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma whose tumors have a PD-L1 combined positive score of 5 or higher.

Latest Oncology Videos

All Oncology News

Dr. Eggermont on Responses to Adjuvant Pembrolizumab in Stage III Melanoma Subtypes

July 9th 2020

Alexander M. M. Eggermont, MD, PhD

Alexander M. M. Eggermont, MD, PhD, discusses responses to adjuvant pembrolizumab in patients with different subtypes of stage III melanoma.

NICE Recommends Frontline Brentuximab Vedotin Combo for Systemic Anaplastic Large Cell Lymphoma

July 9th 2020

Kristi Rosa

The United Kingdom’s National Institute for Health and Care Excellence has recommended brentuximab vedotin (Adcetris) in combination with cyclophosphamide, doxorubicin, and prednisone as a treatment option in treatment-naïve patients with systemic anaplastic large cell lymphoma.

Investigators Leverage Radiomics to Risk Stratify Patients With Early-Stage Lung Cancer

July 9th 2020

Caroline Seymour

Matthew Schabath, PhD, discusses the use of peritumoral and intratumoral radiomic features, where investigators created a model that identified patients with early-stage lung cancer at high risk of experiencing poor survival outcomes.

Marvels in Medicine: Dr. Jordan on Undertaking an Unforeseen Career in Breast Cancer

July 9th 2020

OncLive Staff

In our exclusive interview, Dr. Jordan explains how he became “The Father of Tamoxifen,” details his work with British Special Forces during the Cold War, and discusses how his career in science started by setting his parents’ house on fire.

Experts Focus on 6 Life-Prolonging Treatments for mCRPC

July 9th 2020

Christina T. Loguidice

During a recent OncLive Peer Exchange, a panel of experts in advanced prostate cancer provided their insights on how best to employ 6 therapies that are enabling men with mCRPC to live longer.

Yale Cancer Center Study Shows Breast Cancer Detected Earlier in States with Expanded Medicaid Coverage

July 9th 2020

In a new study by Yale Cancer Center, researchers have demonstrated that in states with expanded Medicaid coverage through the Affordable Care Act a higher percentage of women with breast cancer had their disease diagnosed at an early stage.

FDA Grants Priority Review to Second-Line Pembrolizumab in Relapsed/Refractory Hodgkin Lymphoma

July 9th 2020

Kristi Rosa

The FDA has granted priority review to a new supplemental biologics license application for pembrolizumab monotherapy as a treatment for adult patients with relapsed/refractory classical Hodgkin lymphoma.

CAR T-Cell Therapy in High-Risk Non-Hodgkin Lymphoma

July 9th 2020

Dr. Morris on the Design of the Phase 3 CONDOR Trials in Recurrent Prostate Cancer

July 9th 2020

Michael J. Morris, MD

Michael J. Morris, MD, discusses the ​design of the phase 3 CONDOR trial in men with biochemically recurrent prostate cancer.

Dr. Lin on Developing Systemic Therapies for Patients with Brain Metastases in HER2+ Breast Cancer

July 9th 2020

Nancy U. Lin, MD

Nancy U. Lin, MD, discusses the development of systemic therapies for the treatment of patients with metastatic HER2-positive breast cancer and brain metastases.

Survey Indicates Urgent Need For COVID-19 Testing in Vulnerable Patients With Kidney Cancer

July 9th 2020

Hayley Virgil

Only a small percentage of patients with kidney cancer who are considered to be particularly vulnerable to COVID-19 have actually been tested for infection.

Dr. Ghia on Efficacy and Safety of Acalabrutinib in Relapsed/Refractory CLL

July 9th 2020

Paolo Ghia, MD

Paolo Ghia, MD, PhD, discusses the efficacy and safety of acalabrutinib in the phase 3 ASCEND trial in relapsed/refractory chronic lymphocytic leukemia.

Dr. Roué on Interest With TG-1701 in Ibrutinib-Resistant MCL Models

July 9th 2020

Gaël Roué, PhD

Gaël Roué, PhD, discusses interest regarding the novel irreversible inhibitor TG-1701 in models of ibrutinib (Imbruvica)-resistant mantle cell lymphoma.

Pant Provides Insight on Key ASCO 2020 Data in Gastrointestinal Malignancies

July 9th 2020

Jessica Hergert

Shubham Pant, MD, discusses key data that emerged in the gastrointestinal oncology space from the 2020 ASCO Virtual Scientific Program.

Dr. Leslie on the Benefits With Zanubrutinib in MCL

July 9th 2020

Lori A. Leslie, MD

Lori A. Leslie, MD, discusses the benefits with zanubrutinib (Brukinsa) in the treatment of patients with mantle cell lymphoma.

See All News